This phase I trial tests the safety, side effects, and best dose of camonsertib in combination with stereotactic body radiation therapy in controlling disease in patients with head and neck squamous cell cancer that has come back after a period of improvement (recurrent) or that cannot be removed by surgery (unresectable). Camonsertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Giving camonsertib in combination with stereotactic body radiation therapy may help control disease in patients with recurrent or unresectable head and neck squamous cell cancers.

Start Date13 Feb 2027

Sponsor / Collaborator

National Cancer Institute

NCT05601440

/ RecruitingPhase 2IIT

A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour tissue) for biomarkers to see if patients can participate in the study

Start Date13 Jun 2023

Sponsor / Collaborator

Canadian Cancer Trials Group

NCT05605509

/ CompletedPhase 2IIT

A Phase II Study of RP-6306 in Patients With Advanced Cancer

This study is being done to answer the following questions:
* Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment?
* If there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker?
This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for this type of cancer.

Start Date24 May 2023

Sponsor / Collaborator

Canadian Cancer Trials Group

[+1]

100 Clinical Results associated with Camonsertib

100 Translational Medicine associated with Camonsertib

100 Patents (Medical) associated with Camonsertib

Literatures (Medical) associated with Camonsertib

31 Dec 2026·CLINICAL AND EXPERIMENTAL HYPERTENSION

Bulk and single-cell transcriptomics for identification of potential diagnostic biomarkers associated with pulmonary arterial hypertension and integrated stress response and experimental validation

Article

Author: Li, Haoran ; Qiu, Chenming ; Li, Meiling ; Yang, Yongjian ; Lan, Cong

BACKGROUND:

Pulmonary arterial hypertension (PAH) is a lethal vascular disorder characterized by irreversible remodeling of the pulmonary arteries, but the systematic role of the integrated stress response (ISR)-related genes (ISR-RGs) in its pathogenesis remains unexplored.

OBJECTIVE:

This study aimed to identify and validate ISR-associated potential biomarkers for PAH using integrative bioinformatics, single-cell transcriptomics, and experimental approaches.

METHODS:

We analyzed bulk RNA-seq datasets (GSE38267, GSE131793) and a single-cell RNA sequencing (scRNA-seq) dataset (GSE210248) from PAH patients and controls. A total of 529 ISR-RGs were integrated. Differential expression analysis, machine learning, and functional enrichment analyses were employed to identify potential biomarkers. A diagnostic nomogram was constructed and validated. Immune infiltration, regulatory networks, drug-gene interactions, and molecular docking were further investigated. Key cellular mechanisms were elucidated via scRNA-seq, and biomarker expression was validated using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) and Enzyme-linked immunosorbent assay (ELISA) in clinical whole blood samples.

RESULTS:

We identified four ISR-related diagnostic biomarkers: ABCC4, ATM, SERPINH1, and ZBTB40. These genes showed consistent dysregulation in PAH across multiple datasets and were integrated into a nomogram with good predictive performance (hosmer-lemeshow (HL) test P = 0.432). Gene set enrichment analysis (GSEA) revealed their involvement in translation, neutrophil degranulation, and glucocorticoid pathways. The scRNA-seq highlighted their cell-type-specific expression in T cells and monocytes. Molecular docking identified CAMONSERTIB as a potent ATM-targeting drug (binding energy: -10.2 kcal/mol), and its therapeutic effects on pulmonary arterial hypertension were validated through both animal and cellular models. RT-qPCR and Elisa confirmed upregulation of ABCC4 and downregulation of ATM, SERPINH1 and ZBTB40 in PAH patients.

CONCLUSIONS:

This study identified four novel ISR-related biomarkers for PAH and elucidated their roles in immune infiltration and cellular remodeling. The findings provided new insights into PAH pathogenesis and offered potential tools for diagnosis and targeted therapy.

15 Apr 2026·CLINICAL CANCER RESEARCH

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Article

Author: Roulston, Anne ; Gomez, Gabriela ; Rimkunas, Victoria ; Lheureux, Stephanie ; Koehler, Maria ; Yap, Timothy A. ; Fei, Kezhen ; Baruah, Prasamit ; Ulanet, Danielle ; Fretland, Adrian J. ; Lee, Elizabeth K. ; Cote, Gregory M. ; Zimmermann, Michal ; Carneiro, Benedito A. ; Silverman, Ian M. ; Schonhoft, Joseph D. ; Fontana, Elisa ; Yang, Julia ; Bacque, Emeline S. ; Li, Li ; Plummer, Ruth ; Mettu, Niharika B. ; Mahalingam, Devalingam ; Højgaard, Martin ; Rosen, Ezra Y.

Abstract:

Purpose::

The utility of combination treatment with gemcitabine and camonsertib, an ataxia telangiectasia and Rad3-related kinase inhibitor, in mediating tumor cell death was assessed in preclinical models, prompting clinical investigation. The phase Ib TRESR study (NCT04497116) aimed to evaluate the safety, tolerability, and preliminary efficacy of the combination in patients with advanced solid tumors harboring DNA damage repair (DDR) gene alterations.

Patients and Methods::

Cell lines and tumor xenografts were tested across a range of dose levels and schedules. Patients (N = 76) harboring tumors with DDR gene alterations received camonsertib (80–120 mg) and de-escalating gemcitabine (1,000–100 mg/m2) in 21- or 28-day cycles on an intermittent dosing regimen. Safety, tolerability, and preliminary efficacy were assessed to identify an optimal dosing regimen.

Results::

In preclinical models, low-dose camonsertib (1/3 maximum tolerated dose) and gemcitabine led to tumor regression and was well tolerated with minimal body weight loss observed. In patients, synergistic toxicities were observed, primarily myelosuppression, resulting in gemcitabine de-escalation. The introduction of a 1 week on/1 week off schedule in combination with low-dose gemcitabine allowed for spontaneous neutrophil recovery, fewer dose modifications, and improved tolerability. Tumor responses were primarily observed in patients with gynecologic cancers, with tumor control maintained for greater than 1 year in some patients.

Conclusions::

Camonsertib and low-dose gemcitabine demonstrated preliminary clinical activity, but due to challenging tolerability, further evaluation is warranted to identify the optimal dosing regimen and subset of patients who may benefit most from this combination.

01 Jul 2025·Science Bulletin

Molecular architecture and inhibition mechanism of human ATR-ATRIP

Article

Author: Jian, Lingfei ; Xu, Chenchen ; Cai, Gang ; Wang, Guangxian ; Zheng, Zexuan ; Zhao, Zhanpeng ; Wang, Xuejuan ; Zhang, Qingjun ; Xu, Xinyi ; Wang, Po

The ataxia telangiectasia-mutated and Rad3-related (ATR) kinase is a master regulator of DNA damage response and replication stress in humans. Targeting ATR is the focus of oncology drug pipelines with a number of potent, selective ATR inhibitors currently in clinical development. Here, we determined the cryo-EM structures of the human ATR-ATRIP complex in the presence of VE-822 and RP-3500, two ATR inhibitors currently in Phase II clinical trials, achieving an overall resolution of approximately 3 Å. These structures yield a near-complete atomic model of the ATR-ATRIP complex, revealing subunit stoichiometry, intramolecular and intermolecular interactions, and critical regulatory sites including an insertion in the PIKK regulatory domain (PRD). Structural comparison provides insights into the modes of action and selectivity of ATR inhibitors. The divergent binding modes near the solvent side and in the rear pocket area of VE-822 and RP-3500, particularly their disparate binding orientations, lead to varying conformational changes in the active site. Surprisingly, one ATR-ATRIP complex binds four VE-822 molecules, with two in the ATR active site and two at the ATR-ATR dimer interface. The binding and selectivity of RP-3500 depend on two bound water molecules, which may be further enhanced by the substitution of these bound waters. Our study provides a structural framework for understanding ATR regulation and holds promise for assisting future efforts in rational drug design targeting ATR.

News (Medical) associated with Camonsertib

16 Jul 2025

·www.fiercebiotech.com

Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm

Debiopharm will pay $10 million upfront for the rights to lunresertib.\n Seven months after pressing pause on its plans for its PKMYT1 inhibitor, Repare Therapeutics has found a partner to take the cancer drug forward.Back in January, Repare abandoned phase 3 plans to evaluate the candidate, called lunresertib, in combination with its ATR inhibitor camonsertib for platinum-resistant ovarian cancer. While the biotech continued to assess lunresertib in combination with Debiopharm’s WEE1 inhibitor as part of a collaboration, Repare said at the time that it would halt other plans to develop lunresertib unless a partner can be found.That partner has finally appeared in the form of Debiopharm, which will pay $10 million upfront for the rights to lunresertib. Under the deal, Repare will also be in line for a further $5 million in near-term payments, as well as up to $257 million in potential clinical, regulatory, commercial and sales milestones, and single-digit royalties on sales.Debiopharm will also take over the ongoing study of lunresertib with its WEE1 inhibitor, dubbed Debio 0123.“Based on very promising phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions,” Debiopharm CEO Bertrand Ducrey said in a July 15 post-market release. “We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult-to-treat cancers.”Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of phase 1 trials for its PLK4 inhibitor RP-1664 and the Polθ ATPase inhibitor RP-3467. RP-1664 is currently being evaluated as a monotherapy in adult and adolescent patients with TRIM37-high solid tumors. Meanwhile, Repare is assessing RP-3467 alone and in combination with Lynparza in patients with ovarian cancer, breast cancer, castration-resistant prostate cancer and pancreatic adenocarcinoma, with a readout penciled in for the third quarter.“This agreement builds upon the success of Repare and Debiopharm’s existing collaboration studying the combination of lunresertib and Debio 0123,” Repare’s CEO Steve Forte said in the same release.“Our recent business development efforts have continued to enable Repare to focus on the advancement of our clinical priorities and sustained value creation,” Forte added. “We remain focused on two ongoing phase 1 clinical trials with readouts expected in the second half of 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor and the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor.”

Phase 1License out/inPhase 3Clinical Trial TerminationPhase 2

15 Jul 2025

·firstwordpharma.com

Debiopharm bags rights to Repare’s PKMYT1 inhibitor in $267M deal

Swiss drugmaker Debiopharm entered into an licensing agreement with Repare Therapeutics worth up to $267 million, gaining worldwide rights to the latter’s first-in-class PKMYT1 inhibitor lunresertib.The transaction builds upon the companies’ existing collaboration — established in January last year — which explores the combination of lunresertib with Debiopharm’s Debio 0123, a brain-penetrant, highly selective WEE1 inhibitor. “We believe the synthetic lethality approach of…combination…will allow us to bring this innovative precision therapy to patients with difficult to treat cancers,” said Debiopharm CEO Bertrand Ducrey.As part of the deal announced Tuesday, Repare will receive a $10-million upfront payment and may earn up to $257 million in milestone payments, including up to $5 million in potential near-term payments, in addition to single-digit sales royalties. Debiopharm will assume sponsorship of the MYTHIC study — evaluating lunresertib in combination with Repare’s ATR inhibitor camonsertib for gynaecologic cancers — and be responsible for current and future development activities for lunresertib.Meanwhile, Repare noted the latest arrangement enables it to refocus resources on advancing ongoing Phase I trials of a Polθ ATPase inhibitor (RP-3467) and a PLK4 inhibitor (RP-1664), whilst maintaining involvement in lunresertib development.

License out/inPhase 1

23 Dec 2024

·www.prnewswire.com

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first recipient of a personalized mRNA cancer vaccine, training her immune system to target cancer cells and marking a significant step toward more precise, less toxic treatments. These breakthroughs emphasize the dynamic nature of oncology research and the commitment to delivering groundbreaking therapies to patients worldwide. Key players driving these advancements include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cargo Therapeutics, Inc. (NASDAQ: CRGX), Immuneering Corporation (NASDAQ: IMRX), RenovoRx, Inc. (NASDAQ: RNXT), and Repare Therapeutics Inc. (NASDAQ: RPTX). The article continued: Additionally, the oncology sector has attracted significant investment, with companies like Ottimo Pharma raising $140 million to develop more effective cancer treatments with fewer side effects—highlighting the industry's commitment to addressing the global cancer burden. Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today released a recap of major accomplishments from 2024 and a preview of anticipated milestones for the next 12 months. Following the promising BRACELET-1 readout, Oncolytics expects additional data readouts across its clinical development program in 2025, forming what it believes is a clear pathway to future commercialization opportunities. "This past year produced highly encouraging clinical developments that we believe set the stage for significant progress, headlined by the robust efficacy results from the BRACELET-1 breast cancer study," said Wayne Pisano, Interim CEO and Chair of Oncolytics Biotech's Board of Directors. "In addition, our gastrointestinal cancer program continues to impress, resulting in meaningful collaborations with well-respected experts in the field. Key opinion leaders in both breast and GI cancers continue to be excited by pelareorep's potential as we move into 2025. Based on these insights from leading oncologists, we believe pelareorep has the potential to become a transformational immunotherapy—and that pelareorep-based combination therapies could accelerate our path toward regulatory approval. We are very optimistic about our plans for the next year, and we look forward to showcasing our latest clinical progress early in the new year at the ASCO GI Symposium—an event that could provide key catalysts for our ongoing gastrointestinal cancer programs. Unlike many immunotherapies that struggle to convert 'cold' tumors to 'hot,' pelareorep's unique mechanism of action following intravenous delivery has shown the potential to significantly boost patients' immune responses—making previously unresponsive tumors more susceptible to treatment. I would like to say thank you to our shareholders, clinical collaborators, study sites and their staff, the patients who participate in our trials, and the employees of Oncolytics Biotech who have stepped up in a significant way in the temporary absence of our CEO, Matt Coffey." Oncolytics Biotech continues to advance pelareorep, its innovative immunotherapy for multiple cancer indications. Final efficacy results from the BRACELET-1 study in HR+/HER2- metastatic breast cancer demonstrated a median overall survival benefit exceeding one year and a two-year survival rate nearly double that of paclitaxel monotherapy. These findings, supported by earlier IND-213 data, highlight pelareorep's promise as a groundbreaking treatment option. With FDA alignment on a planned registration-enabling study, Oncolytics Biotech aims to offer improved treatment options for approximately 55,000 U.S. patients annually. Significant progress has also been made in pancreatic cancer. Collaborations with the Global Coalition for Adaptive Research (GCAR) and Roche have set the stage for a registration-enabling study. This builds on the GOBLET study's outcomes, which more than doubled response rates in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients. Additionally, the PanCAN-funded GOBLET cohort, evaluating pelareorep plus mFOLFIRINOX with or without atezolizumab, recently completed safety run-in enrollment and received positive feedback from the Data Safety Monitoring Board. Looking ahead, Oncolytics Biotech will present at the Biotech Showcase on January 13, 2025, and host investor meetings during the J.P. Morgan Healthcare Conference that same week. These events will provide a platform to highlight its clinical advancements and reinforce its commitment to addressing critical unmet needs in oncology. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Cargo Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, recently reported financial results and key program updates. In the Phase 2 FIRCE-1 study, 57 LBCL patients relapsed or refractory to CD19 CAR T-cell therapy have been dosed, with the IDMC recommending the study continue without modification. Interim results are expected in the first half of 2025. For CRG-023, the company plans to submit an IND application for Non-Hodgkin's lymphoma in Q1 2025 and dose the first patient later that year. Preclinical data demonstrating CRG-023's durable anti-tumor activity across multiple antigens will be presented at the 66th ASH Annual Meeting. "We are pleased to report another quarter of strong execution underscored by continued progress in our FIRCE-1, Phase 2 study of firi-cel in addition to meaningful pipeline advancements," said Gina Chapman, President and CEO of CARGO. "With 57 patients dosed and continued, strong manufacturing success, we remain on track to report our interim analysis in the first half of 2025. We also anticipate a clear path forward to advancing CRG-023, our innovative tri-specific CAR T product candidate, into the clinic following our successful pre-IND meeting with the FDA and we are excited to share more at the upcoming ASH meeting." Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company developing universal-RAS/RAF medicines for broad cancer patient populations, recently announced plans to host a virtual Investor Event in early January 2025 to discuss data from its Phase 2a trial of IMM-1-104. The event will feature additional data on IMM-1-104 combined with mGnP in first-line pancreatic cancer, initial data on IMM-1-104 combined with mFFX in first-line pancreatic cancer, and monotherapy results in second-line pancreatic cancer. Initial PK, PD, and safety data from the Phase 1 portion of the Phase 1/2a trial of IMM-6-415 will also be presented. Access details for the event will be shared closer to the date. "We are excited to soon share additional data from our Phase 2a study of IMM-1-104 in patients with pancreatic cancer," said Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering. "Pancreatic cancer patients urgently need new options that enable them to live longer and feel better. The FDA has recently granted IMM-1-104 Orphan Drug designation in pancreatic cancer, along with Fast Track designations in first and second-line pancreatic cancer, and advanced melanoma. We look forward to building on our September update with additional data from the Phase 2a study of IMM-1-104." RenovoRx, Inc. (NASDAQ: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared local drug-delivery platform, recently announced that SCRI Oncology Partners in Nashville, TN, has begun enrolling patients with locally advanced pancreatic cancer (LAPC) in the pivotal Phase III TIGeR-PaC clinical trial. This study leverages RenovoRx's TAMPTM (Trans-Arterial Micro-Perfusion) therapy platform, which delivers gemcitabine directly to tumors via the RenovoCath system using pressure-mediated delivery. The trial is comparing this innovative drug-device combination to the current standard-of-care systemic intravenous chemotherapy, with the goal of improving outcomes for LAPC patients. "On an annual basis, SCRI and its affiliated sites reach one in five patients with cancer and is responsible for enrolling thousands of patients on clinical trials," said Leesa Gentry, Chief Clinical Officer of RenovoRx. "We believe this collaboration will assist the Company in both accelerating patient enrollment in our pivotal Phase III TIGeR-PaC clinical trial and driving the study towards its expected enrollment completion in the first half of 2025." Repare Therapeutics Inc. (NASDAQ: RPTX), a leading clinical-stage precision oncology company, recently reported positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial evaluating the combination of lunresertib (a first-in-class precision oncology small molecule PKMYT1 inhibitor) and camonsertib (Lunre+Camo) (a potential best-in-class oral small molecule inhibitor of ATR) at the recommended Phase 2 dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. "We are encouraged by the strong response and the clear benefit we observed in patients with endometrial and platinum-resistant ovarian cancers in the MYTHIC clinical trial," said Lloyd M. Segal, President and CEO of Repare. "These patients need new treatment options and our results support the potential for Lunre+Camo to make a real, positive difference if approved, particularly as a chemotherapy alternative. We have positive feedback from regulatory agencies in both the US and Europe and we look forward to getting started on a registrational Phase 3 trial of Lunre+Camo in endometrial cancer in the second half of 2025." Source: CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2ImmunotherapyClinical ResultPhase 1

100 Deals associated with Camonsertib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver metastases	Phase 2	United States	Repare Therapeutics, Inc.	30 Sep 2022
Metastatic Solid Tumor	Phase 2	United States	Repare Therapeutics, Inc.	30 Sep 2022
Recurrent Chronic Lymphoid Leukemia	Phase 2	United States	Repare Therapeutics, Inc.	23 Sep 2022
Advanced Malignant Solid Neoplasm	Phase 2	United States	Repare Therapeutics, Inc.	22 Jul 2020
Advanced Malignant Solid Neoplasm	Phase 2	Canada	Repare Therapeutics, Inc.	22 Jul 2020
Advanced Malignant Solid Neoplasm	Phase 2	Denmark	Repare Therapeutics, Inc.	22 Jul 2020
Advanced Malignant Solid Neoplasm	Phase 2	United Kingdom	Repare Therapeutics, Inc.	22 Jul 2020
Solid tumor	Phase 2	United States	Roche Pharma AG	22 Jul 2020
metastatic non-small cell lung cancer	Phase 2	United States	Hoffmann-La Roche, Inc.	27 Dec 2017
metastatic non-small cell lung cancer	Phase 2	Australia	Hoffmann-La Roche, Inc.	27 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05405309 (CORONADO CLL, CTgov)	Phase 1/2	Recurrent Chronic Lymphoid Leukemia	5	Olaparib+RP-3500 (Phase Ib: Dose Level -1)	lxdandtxwr = hngxpycxpl kwmgdyzkjg (sqbfqwtckd, bjzprmmjfa - txgoussrfc) View more	-	03 Jun 2025
NCT05405309 (CORONADO CLL, CTgov)	Phase 1/2	Recurrent Chronic Lymphoid Leukemia	5	Olaparib+RP-3500 (Phase Ib: Dose Level 1)	snrmwqcacm(gtvvahzvge) = alazhdyedd xirmyeyrzr (ncsngdeafd, xrmtfrhokh - bvrpofzqcl) View more	-	03 Jun 2025
NCT04855656 (MYTHIC, AACR2025)	Phase 1	Ovarian Cancer \| Endometrial Carcinoma MSI high	67	Lunresertib 80mg BID	jfiifctznm(atrviopwoy) = 26.9% dsepihdyrv (fmcnldrtdd ) View more	Positive	29 Apr 2025
NCT04855656 (MYTHIC, AACR2025)	Phase 1	Ovarian Cancer \| Endometrial Carcinoma MSI high	67	Camonsertib 80mg QD		Positive	29 Apr 2025
NCT04855656 (MYTHIC, Company_Website) Manual	Phase 1	Endometrial Carcinoma \| Platinum-Resistant Ovarian Carcinoma	51	Lunresertib + Camonsertib (Endometrial Cancer)	vmfmhbhshn(icygmkysaa) = lygimyifki pnqlirkkki (xtnhzuxssn ) View more	Positive	12 Dec 2024
NCT04855656 (MYTHIC, Company_Website) Manual	Phase 1		51	Lunresertib + Camonsertib (Platinum-Resistant Ovarian Cancer)	vmfmhbhshn(icygmkysaa) = xkeozfswnn pnqlirkkki (xtnhzuxssn ) View more	Positive	12 Dec 2024
NCT04497116 (TRESR, ESMO2024)	Phase 1/2	Advanced cancer ATM loss-of-function	55	Camonsertib (cam) monotherapy	bwhcpeuytp(qntgeenxev) = orqephuvur setdeprclq (euppkqjynq ) View more	Positive	14 Sep 2024
NCT04497116 (Pubmed)	Phase 1	Advanced Malignant Solid Neoplasm	120	Camonsertib	dkitakmlno(qjzbalzeyx) = ejyhldivlh hkizkjmoek (yjetygxsxd ) View more	-	05 Jun 2023
NCT04972110 \| NCT04497116 (AACR2023) Manual	Phase 1	Solid tumor DNA damage response alterations	99	camonsertib+talazoparib+niraparib/olaparib	ahxvqoyljc(xigghwvpcl) = ghwwcokbsr zhtdpvrpij (deslubebnv ) View more	Positive	14 Apr 2023
NCT04497116 (TRESR, AACR2021) Manual	Phase 1	Advanced Malignant Solid Neoplasm \| Ataxia Telangiectasia	62	RP-3500	cohioarbrr(qnqdvvvtes) = none wlewbfqkyz (ttybjqevev ) View more	Positive	01 Dec 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis